By Ilan Zipkin
Staff Writer

Protein Design Labs Inc. is taking advantage of basic research done by one of its scientific founders to expand its R&D pipeline beyond the company's core humanized and human antibody technology platform. PDLI announced its first partnership last week, with Eli Lilly and Co., for the microbial pathogenesis program.